SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN)

CAPS Rating: 5 out of 5

A biopharmaceutical company, which is engaged in the development and commercialization of novel therapeutics to treat life-threatening diseases.

Recs

0
Player Avatar DaddyRebel (< 20) Submitted: 1/22/2013 6:47:32 AM : Outperform Start Price: $4.12 SCLN Score: +44.09

After the downfall in november ready to jump towards USD 7,50

Featured Broker Partners


Advertisement